Category

• Pipeline2
• Events1
• Products1

Organizations

• Bausch + Lomb54
• Eyes On Eyecare38
• Alcon, Inc.30
• American Optometric Association29
• Glaukos24
• Harrow23
• Regeneron19
• Aldeyra Therapeutics17
• American Academy Of Ophthalmology17
• Coopervision17

Tags

• Retina4
• FDA3
• Cell Therapy3
• Inherited Retinal Disease2
• Macular2
• Fda Approval1
• Ophthalmology Tech Forum1
• Clinical Trials1
• Cornea1
• Gene Therapy1

• Organizations: Neurotech Pharmaceuticals✕

Clear all

Products

FDA approves Neurotech's ENCELTO cell therapy for MacTel

Approval of revakinagene taroretcel-lwey is the first-ever for the treatment of this rare, neurodegenerative retinal disease. 

Pipeline

FDA extends Neurotech's BLA PDUFA date for MacTel therapy

Review period of NT-501, an encapsulated cell therapy, now has a target date of March 2025.

Events

KOLs eye the future of genetic engineering and cell transplantation

Industry leaders from four leading ophthalmic companies debut the latest clinical developments in cell-based therapeutics.

Pipeline

Neurotech Pharma earns BLA priority review for MacTel cell therapy

Investigational ocular implant is designed to slow progression of gradual central vision deterioration in rare neurodegenerative retinal disease.